3'-O- and 5'-O-Propargyl Derivatives of 5-Fluoro-2'-Deoxyuridine: Synthesis, Cytotoxic Evaluation and Conformational Analysis. 2016

Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
a Institute of Bioorganic Chemistry, Polish Academy of Sciences , Noskowskiego St 12/14, 61-704 PoznaƄ , Poland.

A series of new 3'-O- and 5'-O-propargyl derivatives of 5-fluoro-2'-deoxyuridine (1-4) was synthesized by means of propargyl reaction of properly blocked nucleosides (2,4), followed by the deprotection reaction with ammonium fluoride. The synthesized propargylated 5-fluoro-2'-deoxyuridine analogues (1-4) were evaluated for their cytotoxic activity in three human cancer cell lines: cervical (HeLa), oral (KB) and breast (MCF-7), using the sulforhodamine B (SRB) assay. The highest activity and the best SI coefficient in all of the investigated cancer cells were displayed by 3'-O-propargyl-5-fluoro-2'-deoxyuridine (1), and its activity was higher than that of the parent nucleoside. The other new compounds exhibited moderate activity in all of the used cell lines.

UI MeSH Term Description Entries
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D005260 Female Females
D005467 Floxuridine An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. FUdR,Fluorodeoxyuridine,5-FUdR,5-Fluorodeoxyuridine,5 Fluorodeoxyuridine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
June 1996, Chemical & pharmaceutical bulletin,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
May 1993, Journal of medicinal chemistry,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
January 1985, Biochemical and biophysical research communications,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
August 1983, Journal of medicinal chemistry,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
June 2016, European journal of medicinal chemistry,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
January 1969, Journal of medicinal chemistry,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
November 1965, Biochemical pharmacology,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
January 1970, Journal of medicinal chemistry,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
June 1998, Anti-cancer drug design,
Dagmara Baraniak, and Daniel Baranowski, and Piotr Ruszkowski, and Jerzy Boryski
July 1995, Journal of medicinal chemistry,
Copied contents to your clipboard!